World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
52604
World Ranking
10256
National Ranking
319

Julien Mazieres publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Julien Mazieres sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 648 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Julien Mazieres D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Julien Mazieres sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Julien Mazieres is affiliated with Paul Sabatier University in France and has contributed extensively to the field of medicine, focusing primarily on pulmonary and respiratory medicine, oncology, and cancer research. Their scholarly output encompasses a broad range of topics related to lung cancer treatments, mutations, and diagnostics, alongside work in cancer immunotherapy and biomarkers.

The scientist's recent publications include the following notable papers:

  • First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer, 2020, New England Journal of Medicine
  • Trastuzumab Deruxtecan in HER2 -Mutant Non-Small-Cell Lung Cancer, 2021, New England Journal of Medicine
  • Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations, 2020, New England Journal of Medicine
  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study, 2020, Journal of Clinical Oncology
  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study, 2020, The Lancet Oncology

Mazieres collaborates frequently with several researchers within the oncology and respiratory fields. The most common co-authors include:

  • Enriqueta Felip
  • Fabrice Barlési
  • Benjamin Besse
  • Alexis B. Cortot
  • Denis Moro-Sibilot

Their publications appear predominantly in established journals, reflecting consistent research engagement in lung cancer and related fields. Frequent publication venues include:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Revue des Maladies Respiratoires Actualités
  • Lung Cancer

Julien Mazieres's research spans multiple interconnected fields of study:

  • Medicine
  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Surgery

Their research topics reflect a strong emphasis on the clinical and molecular aspects of lung cancer, cancer biomarkers, and genomics. Main topics they focus on include:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • HER2/EGFR in Cancer Research

Best Publications

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

    Luis Paz-Ares;Alexander Luft;David Vicente;Ali Tafreshi

  • Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial

    Louis Fehrenbacher;Alexander Spira;Marcus Ballinger;Marcin Kowanetz

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres

  • Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

    J. Mazieres;A. Drilon;A. Lusque;L. Mhanna

  • Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

    Fabrice Barlesi;Julien Mazieres;Jean-Philippe Merlio;Didier Debieuvre

  • Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

    Gérard Zalcman;Gérard Zalcman;Julien Mazieres;Jacques Margery;Laurent Greillier

  • Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

    Laura Mezquita;Edouard Auclin;Roberto Ferrara;Melinda Charrier

  • An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

    David Planchard;Benjamin Besse;Harry J M Groen;Pierre-Jean Souquet

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Todd M. Bauer;Filippo de Marinis;Enriqueta Felip

  • Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

    Julien Mazières;Solange Peters;Benoit Lepage;Alexis B. Cortot

  • Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

    Roberto Ferrara;Laura Mezquita;Matthieu Texier;Jihene Lahmar

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik;Enriqueta Felip;Remi Veillon;Hiroshi Sakai

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.

    Marina Chiara Garassino;Jennifer G. Whisenant;Li Ching Huang;Annalisa Trama

  • Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

    Charles M Rudin;Mark M Awad;Alejandro Navarro;Maya Gottfried

  • A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

    Luis Paz-Ares;David Vicente;Ali Tafreshi;Andrew Robinson

  • Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

    Arnaud Scherpereel;Julien Mazieres;Laurent Greillier;Sylvie Lantuejoul

  • Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    David Planchard;Tae Min Kim;Julien Mazieres;Elisabeth Quoix

Frequent Co-Authors

Fabrice Barlesi
Fabrice Barlesi Institut Gustave Roussy
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Jacques Cadranel
Jacques Cadranel Université Paris Cité
Nicolas Girard
Nicolas Girard Institute Curie
David Planchard
David Planchard Institut Gustave Roussy
Silvia Novello
Silvia Novello University of Turin
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
David M. Jablons
David M. Jablons University of California, San Francisco
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Martin Reck
Martin Reck LungenClinic Grosshansdorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens the door to numerous related online degrees and flexible career options, whether you are beginning or advancing your healthcare journey. Many students are searching for high-quality programs that balance cost, convenience, and future job prospects.

If your interest extends to healthcare leadership, consider enrolling in one of the cheapest MHA programs to pursue a master’s in healthcare administration online. For nursing professionals aiming for the next level, a 1 year DNP program online can offer an accelerated path to a Doctor of Nursing Practice without long campus commitments.

Pharmacists or students considering pharmacy can now earn their doctorate from home through accredited online Pharm D programs. Meanwhile, the IT side of healthcare is growing fast; a health information management degree online can prepare you for roles managing patient information and technology in medical settings.

These online degrees support a range of career trajectories and can help you enter or advance in the healthcare sector from wherever you are.

Best Scientists Citing Julien Mazieres

Trending Scientists

Recently Published Articles